更正：部分国家心血管疾病复方制剂的可及性与可负担性调查。
Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries.
作者信息
Satheesh Gautam, Gyawali Bishal, Sun Marie France Chan, Huffman Mark D, Banerjee Amitava, Perel Pablo, Murphy Adrianna
机构信息
The George Institute for Global Health, Hyderabad, India.
Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
出版信息
Glob Heart. 2024 Aug 13;19(1):64. doi: 10.5334/gh.1350. eCollection 2024.
Abstract
[This corrects the article DOI: 10.5334/gh.1335.].
摘要
[本文更正了文章的数字对象标识符：10.5334/gh.1335。]
相似文献
1
Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries.更正：部分国家心血管疾病复方制剂的可及性与可负担性调查。
Glob Heart. 2024 Aug 13;19(1):64. doi: 10.5334/gh.1350. eCollection 2024.
2
A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries.某些国家用于心血管疾病的复方药的可及性和可负担性调查。
Glob Heart. 2024 Jul 1;19(1):56. doi: 10.5334/gh.1335. eCollection 2024.
3
Polypills: essential medicines for cardiovascular disease secondary prevention?复方药：心血管疾病二级预防的基本药物？
J Am Coll Cardiol. 2014 Apr 15;63(14):1368-70. doi: 10.1016/j.jacc.2013.08.1665. Epub 2014 Feb 19.
4
Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability.发展中国家心血管疾病和高血压药物的可及性：基本药物清单、价格、可获得性及可负担性分析
J Am Heart Assoc. 2020 May 5;9(9):e015302. doi: 10.1161/JAHA.119.015302. Epub 2020 Apr 25.
5
Uses of polypills for cardiovascular disease and evidence to date.复方药物在心血管疾病中的应用及现有证据。
Lancet. 2017 Mar 11;389(10073):1055-1065. doi: 10.1016/S0140-6736(17)30553-6.
6
Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality.将复方制剂纳入《世界卫生组织基本药物标准清单》第23版以预防心血管疾病：迈向降低全球心血管发病率和死亡率的重要一步。
Glob Heart. 2024 Feb 26;19(1):24. doi: 10.5334/gh.1310. eCollection 2024.
7
The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran).伊朗德黑兰省心血管疾病二级预防药物的可及性与可负担性
Iran J Pharm Res. 2018 Winter;17(Suppl):64-72.
8
Access to cardiovascular medicines in low- and middle-income countries: a mini review.中低收入国家的心血管药物可及性：小型综述。
Glob Health Res Policy. 2023 May 23;8(1):17. doi: 10.1186/s41256-023-00301-6.
9
The feasibility of polypill for cardiovascular disease prevention in Asian Population.亚洲人群心血管疾病一级预防中使用复方药的可行性。
J Clin Hypertens (Greenwich). 2021 Mar;23(3):545-555. doi: 10.1111/jch.14075. Epub 2020 Oct 21.
10
Polypills for the prevention of Cardiovascular diseases.用于预防心血管疾病的复方制剂
Expert Opin Investig Drugs. 2016 Nov;25(11):1255-1264. doi: 10.1080/13543784.2016.1236912. Epub 2016 Sep 22.
引用本文的文献
1
Perceived benefits, costs, and relationships on provincial doctors' inclination to participate in urban-rural medical consortia in Central China: a social exchange theory perspective.从社会交换理论视角看中部地区省级医生参与城乡医疗联合体的感知收益、成本及关系
Front Public Health. 2025 Jan 7;12:1474164. doi: 10.3389/fpubh.2024.1474164. eCollection 2024.
本文引用的文献
1
A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries.某些国家用于心血管疾病的复方药的可及性和可负担性调查。
Glob Heart. 2024 Jul 1;19(1):56. doi: 10.5334/gh.1335. eCollection 2024.
Zotero 插件